CG Invites Co., Ltd.
Biopharma advancing precision medicine with drugs, mRNA vaccines, and digital therapeutics.
083790 | KO
Overview
Corporate Details
- ISIN(s):
- N/A
- LEI:
- Country:
- South Korea
- Address:
- 서울특별시 강서구 마곡중앙8로 38 마곡동, 강서구
- Website:
- https://cginvites.com/en
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
CG Invites Co., Ltd. is a biopharmaceutical company specializing in digital genomics and personalized precision medicine. Leveraging its core competency in developing novel chemical and biological drugs—such as Acelex (osteoarthritis), Ivaltinostat (pancreatic cancer), and Camrelizumab (immuno-oncology)—the company has expanded its focus to several key areas. These include whole genome sequencing, contributing to large-scale bio-data projects; the development of personalized, mRNA-based cancer vaccines targeting tumor-specific neoantigens; and digital therapeutics (DTx), exemplified by its HealthOnG platform for diabetes management. The company's strategy is to innovate within the digital genome market by integrating its drug development expertise with cutting-edge genomic and digital health technologies.
This is a Fraction of the Available Data.
You're viewing a limited, static snapshot. Professionals use our API to get real-time, AI-ready data for CG Invites Co., Ltd. and 9,000+ other companies.
Stop analyzing yesterday's news. Start building a real-time advantage.
Request Enterprise API AccessFilings
Automate Your Workflow. Get a real-time feed of all CG Invites Co., Ltd. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Need More History? Access decades of standardized financials for CG Invites Co., Ltd. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
